CHIR 98014

Key Product Details

Product Description

CHIR 98014 is a highly potent and selective GSK-3 inhibitor (IC₅₀ values are 0.58 and 0.65 nM for the β and α isoforms, respectively). Exhibits >500-fold selectivity for GSK-3β over a range of other kinases. Improves insulin sensitivity of muscle strips from diabetic rats in vitro and decreases insulin and glucose levels in the oral glucose tolerance test in vivo. Activates Wnt signaling in human adipose stem cells (hASC) and promotes the production of definitive endoderm. Has been used in protocols to derive epicardial cells from hPSCs.

Product Specifications for CHIR 98014

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CHIR 98014

The following data is based on the product molecular weight 486.31.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	10.28 mL	51.41 mL	102.82 mL
1 mM	2.06 mL	10.28 mL	20.56 mL
2 mM	1.03 mL	5.14 mL	10.28 mL
10 mM	0.21 mL	1.03 mL	2.06 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 13 publications citing the usage of this product.

• Paik and Wu Simply derived epicardial cells. Nat.Biomed.Eng. 2017 PMID: 29354320
• Huang Activation of Wnt/β-catenin signalling via GSK3 inhibitors direct differentiation of human adipose stem cells into functional hepatocytes. Sci.Rep. 2017 PMID: 28094799
• Ring Selective glycogen synthase kinase 3 inhibitors potentiate Ins activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003 PMID: 12606497

Product Documents for CHIR 98014